DNA methylation occurs predominantly at cytosines that precede guanines in dinucleotide CpG sites; it is one of the most important mechanisms for epigenetic DNA regulation during normal development and for aberrant DNA in cancer. To determine the feasibility of DNA methylation studies in the postmortem human brain, we evaluated brain samples with variable postmortem artificially increased delays up to 48 hours. DNA methylation was analyzed in selected regions of MAPT, APP, and PSEN1 in the frontal cortex and hippocampus of controls (n = 26) and those with Alzheimer disease at Stages I to II (n = 17); Alzheimer disease at Stages III to IV (n = 15); Alzheimer disease at Stages V to VI (n = 12); argyrophilic grain disease (n = 10); frontotemporal lobar degeneration linked to tau mutations (n = 6); frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions (n = 4); frontotemporal lobar degeneration with motor neuron disease (n = 3); Pick disease (n = 3); Parkinson disease (n = 8); dementia with Lewy bodies, pure form (n = 5); and dementia with Lewy bodies, common form (n = 15). UCHL1 (ubiquitin carboxyl-terminal hydrolase 1 gene) was analyzed in the frontal cortex of controls and those with Parkinson disease and related synucleinopathies. DNA methylation sites were very reproducible in every case. No differences in the percentage of CpG methylation were found between control and disease samples or among the different pathological entities in any region analyzed. Because small changes in methylation of DNA promoters in vulnerable cells might have not been detected in total homogenates, however, these results should be interpreted with caution, particularly as they relate to chronic degenerative diseases in which small modifications may be sufficient to modulate disease progression.
INTRODUCTION
DNA methylation is one of the most important mechanisms for epigenetic silencing in mammals; it occurs predominantly at cytosines that precede guanines in dinucleotide CpG sites (1) . Approximately half of the human gene promoters contain CpG-rich regions with lengths of 0.5 kb to several kb known as CpG islands. Regions that are actively transcribed generally have promoter regions with predominantly unmethylated CpG islands, whereas transcriptionally silent regions have abundant methylated CpG sites (2) . Most CpG islands are located in the 5 ¶ UTR regions and the first exon (3) . DNA methylation is a normal process that occurs in mammalian embryonic development, X-chromosome inactivation, and repression of proviral genes and endogenous transposons (1) . Methylation of CpG islands is usually accompanied by posttranslational histone modifications that modulate gene expression (4, 5) . For example, MeCP2 is a methyl CpG-binding protein that recruits members of chromatin remodeling complexes to repress gene transcription (6) . Several mutations in MeCP2 genes have been reported in Rett syndrome, one of the most common genetic causes of mental retardation in females (7) .
CpG islands are usually unmethylated in normal cells (8) , whereas hypermethylation of CpG islands is a major event in many cancers (9) . The role of DNA methylation in the brain is an emerging field of scientific analysis. It was recently reported that DNA methylation signatures exist for every cerebral region (10) and that neuronal DNA methylation is modified with life span (11) .
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MATERIALS AND METHODS

Case Material
To document variations in DNA methylation profiles with postmortem delay, we extracted genomic DNA from the frontal cortex of 5 different subjects obtained after a short postmortem delay and immediately frozen or stored at 4-C for 3, 6, 15.5, 24, or 48 hours and then frozen to mimic variable postmortem delay in tissue processing (Table 1) .
Cases studied for CpG methylation in MAPT, PSEN1, APP, and UCHL1 were as follows: controls (n = 26), PD Stages 3 and 4 (n = 8), DLBp (n = 5), DLBc (n = 15), AD Stages I to II (n = 17), AD Stages III to IV (n = 15), AD Stages V to VI (n = 12), AGD (n = 10), FTLD-tau (n = 6), FTLD-U (n = 4), FTLD-MND (n = 3), and PiD (n = 3). The total number of cases was 124, with 75 males (27) . §Positions with respect to the first transcription start site described by Andreadis et al (29) .
kIntronic location. ¶Transcription start site described by Rogaev et al (31) . LTranscription start site established by Salbaum et al (33) . and 49 females. Postmortem delay was 2 to 20 hours. The neuropathologic diagnoses were made according to well-established criteria for AD (15, 16) , AGD (17), FTLD-tau (18), FTLD-U and FTLD-MND (19, 20) , PD (21), DLB (20Y23), and PiD (24, 25) . Clinical and neuropathologic data are summarized in Table 2 .
Cell Culture
HeLa and SH-SY5Y cells were maintained in Dulbecco minimal essential medium (Invitrogen, El Prat de Llobregat, Spain) supplemented with 10% fetal bovine serum and 2 mmol/L L-glutamine. Both cell lines were grown at 37-C in a humidified atmosphere of 5% carbon dioxide.
DNA Purification and Bisulfite Treatment
Genomic DNA from human postmortem frozen brain samples was purified using DNeasy Tissue kit (Qiagen, Las Matas, Madrid, Spain) following the indications of the supplier. Bisulfite DNA treatment was performed using EZ DNA Methylation kit (Zymo Research, Ecogen, Barcelona, Spain). One microgram of genomic DNA for every sample was mixed with 5 KL of M-dilution buffer in a final volume of 50 KL and incubated at 37-C for 15 minutes. After incubation, 100 KL of prepared CT conversion reagent was added to each sample. The tubes were then incubated in the dark with a thermal cycler (GeneAmp PCR System 9700, Applied Biosystems, Madrid, Spain) as follows: 20 cycles at 95-C for 30 seconds and 50-C for 15 minutes followed by a last hold at 4-C for 10 minutes (the total duration is approximately 5.5 hours). The samples were then mixed with 400 KL of M-binding buffer and loaded into a Zymo-Spin I column and centrifuged (Q10,000 Â g) for 30 seconds. The columns were washed with 200 KL of M-wash buffer and centrifuged at full speed for 30 seconds. After this, 200 KL of M-desulphonation buffer was added at room temperature for 15 minutes. After incubation, the columns were centrifuged at full speed for 30 seconds and then washed twice with 200 KL of M-wash buffer at full speed for 30 seconds and 1 minute. A third centrifugation without buffer was performed to remove wash buffer residues. Finally, 100 KL of water was added to the column, and DNA was eluted in a new tube after a centrifugation at 3,000 Â g for 30 seconds.
Quantitative DNA Methylation Analysis DNA regions surrounding transcriptional start sites of RAGE, ADORA2A, UCHL1, MAPT, PSEN1, and APP (26Y33) Table 1 that had been subjected to artificially increased postmortem delay for 6, 15.5, 24, or 48 hours after autopsy performed between 2 and 5 hours after death. No significant differences are seen in the methylation levels of each specific site at different time points of postmortem delay up to 48 hours.
were analyzed. Primers for each region were designed using MethPrimer (http://www.urogene.org/methprimer/). Each reverse primer presented a T7 promoter tagged to obtain an appropriate product for in vitro transcription and an 8-bp insert to prevent abortive cycling. The forward primers contain a 10-mer tag to balance the polymerase chain reaction (PCR) primer length. The sequence of each primer used for amplification of bisulfite-treated DNA (tags incorporated are labeled in lower case and underlined) is indicated as follows: every set of primers for 30 seconds (Table 3) , 72-C for 1 minute, and a last hold at 72-C for 3 minutes. Then, 0.5 KL of every PCR product was checked in 1.5% agarose gel to confirm successful PCR amplification. The rest of the PCR product of each sample was sent to SEQUENOM (Hamburg, Germany) to be analyzed using the MassArray System platform (34, 35) . This technology consists of the analysis of DNA methylation by gene-specific amplification of bisulfite-treated DNA followed by in vitro transcription, base-specific cleavage, and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) analysis without cloning of the PCR products. Because CpG sites that are very close to each other cannot be differentiated in the MALDI-TOF analysis, the percentage of DNA methylation is considered to be the same for each.
UCHL1 methylation levels were quantified in non-UCHL1-expressed HeLa cells (28) 
Statistical Analysis
Statgraphics Plus v5 software was used for statistical analysis.
RESULTS
DNA Methylation Is Preserved in Human Postmortem Brain Samples
The 4 CpG sites quantified in RAGE were highly methylated (especially CpG Site Numbers 4 and 5); this methylation profile was not modified with artificially prolonged postmortem delay up to 48 hours (Fig. 1A) . Similar results were obtained for all 13 CpG sites in ADORA2A (Fig. 1B) . The region analyzed, 5 ¶ upstream region of Exon 0 in MAPT, which was predicted as a CpG island by MethPrimer software, was lightly methylated, and no increase in methylcytosine content was observed with a progressive postmortem delay (Fig. 1C) .
Analysis of DNA Methylation in Noncoding Regions of Genes Related With AD and Other Tauopathies MAPT
The percentages of DNA methylation were analyzed in 3 MAPT regions, a locus surrounding Exon 0 (Fig. 2) and 2 intronic loci (Figs. 3, 4) . The analysis revealed low levels of DNA methylation in the 5 ¶ upstream flanking region to Exon 0, only detecting around 20% to 40% of DNA methylation for CpG Sites 5, 6, and 13. No differences in the frontal cortex were detected between AD and tauopathies and agematched control samples. Moreover, no differences were seen between these groups and other degenerative diseases, including FTLD-U, FTLD-MNS, PD, and DLB. Finally, no differences were observed in the hippocampus among different stages of AD, AGD, and age-matched controls (Fig. 2) . The analysis of the other 2 MAPT regions in the intronic region close to and distant from Exon 0 was restricted to AD, tauopathies, and FTLD, and to AD and tauopathies, respectively. The analysis of the 3 ¶ downstream flanking region to Exon 0 (positions at +1411/+1978 and at +54336/+54905) presented a technical problem because base-specific cleavage of the in vitro transcription product was not discriminated by MALDI-TOF, obtaining the same percentage of DNA methylation for CpG Site Numbers 3 and 7, CpG site Numbers 15 to 17 and 33 (Fig. 3) , and CpG Site Numbers 1 and 19 (Fig. 4) . The global DNA methylation profile for these 2 loci is similar to that observed in the 5 ¶ upstream flanking region to Exon 0, including low levels of DNA methylation and no differences between control and diseased cases in the frontal cortex and hippocampus. The only difference occurred at Positions 1 and 19 in the +54336/ +54905 region in PiD, where increased methylation was observed in comparison with controls (p G 0.01, analysis of variance with post hoc Scheffé test) (Fig. 4) .
PSEN1
DNA methylation levels in the regions of PSEN1 analyzed were very low, and no differences were seen among controls and diseased cases in frontal cortex and hippocampus. Cases analyzed included AD, tauopathies, FTLD-U, FTLD-MNS, PD, DLBp, DLBc, and controls (Fig. 5) .
APP
Low CpG methylation in the APP gene promoter region close to the transcriptional start site occurred in control and diseased cases. No significant differences were seen among AD cases and cases with Lewy bodyYassociated pathology (the only ones examined for APP); these did not differ from percentages of methylation encountered in controls (Fig. 6) . In contrast, a high percentage of CpG methylation was present in a distal 5 ¶ region of APP promoter. Again, no differences were seen among AD at different stages and Lewy body diseases (PD, DLBp, and DLBc) or between diseased cases and controls (Fig. 6 ).
UCHL1
A low percentage of DNA methylation was observed in controls. This pattern was not modified in PD, DLBp, and DLBc, although there were individual variations in Sites 6 to 8 and 16 to 18 (Fig. 7) .
DISCUSSION
MassArray platform has been used to determine the percentage of DNA methylation in selected loci of gene promoters related to AD and other tauopathies. This technology consists of the analysis of DNA methylation by gene-specific amplification of bisulfite-treated DNA followed by in vitro transcription, base-specific cleavage, and MALDI-TOF without cloning of the PCR products. Although this is a robust method, it is worth stressing that CpG sites very close to each other cannot be differentiated in the MALDI-TOF analysis, and the percentage of DNA methylation is then considered to be the same for both. The MassArray technique does not evaluate non-CpG methylation (34, 35) .
The genes for the study of possible effects of postmortem delay on CpG methylation were selected for several reasons. On 1 hand, DNA methylation in the RAGE promoter seems to be reduced with age (36) , whereas the region analyzed in ADORA2A is heavily methylated. Finally, the region analyzed in MAPT is poorly methylated, and the selection of this gene was within the context of the study of genesVthe encoded proteins of which are associated with AD. No modifications in CpG methylation with artificially increased postmortem delay up to 48 hours were observed in the regions examined in RAGE, ADORA2A, and MAPT. Recent studies have also shown that postmortem delay does not affect methylation of histone tails (37) .
MAPT contains 16 exons and is devoid of TATA or CAAT boxes. A CpG island encompasses Exon 0 and spans more than 3 kb (29); 11 CpG islands are present in the adjacent Intron 0 (30) . Previous studies have shown a decrease with age in the total number of methylcytosines in the 5 ¶ f lanking region close to Exon 0 in the human parietal cortex (38) . Because 3 CpG islands analyzed here (one located upstream from Exon 0 and the other 2 in Intron 0) show a low percentage of DNA methylation in control and disease cases, this is difficult to assess. Interestingly, the same patterns were observed in control and disease cases, and similar methylation sites occurred in the frontal cortex and hippocampus. Moreover, no differences were seen among the different stages in AD or among AD, AGD, FTLD-tau, FTLD-U, FTL-MND, PD, DLBp, and DLBc. The only exception was PiD, in which increased DNA methylation was noted in CpG Sites 1 and 19. These results must be critically examined, however, first because the number of PiD cases was small, and second because in silico analysis did not reveal any putative binding for a transcription factor candidate in these particular sites as revealed by bioinformatic analysis with MatInspector software (see Supplemental Figure 2 , Supplemental Digital Content 2, http:// links.lww.com/A1409).
Recent studies have shown that PSEN1 is hypomethylated (11) , and that no variations in DNA methylation are found in AD brains (39) . We corroborate these findings at the different stages in AD, and we point out that modifications are also not observed in the other tauopathies, that is, FTLD-U and FTLD-MND, or in PD, DLBp, and DLBc.
APP is also GC rich, contains multiple initiation sites, and lacks a TATA box (33) . Previous studies have shown a reduction in methylcytosines in the promoter region of APP with age, suggesting that demethylation may have some role in A-amyloid deposition in the aged brain (36, 40) . These findings have not been replicated using a more sensitive technique in a larger number of cases, however (39) . The present findings show no differences in the percentages of CpG methylation sites among different pathological conditions and age-matched controls.
Finally, a previous study revealed 35 CpG sites in the UCHL1 promoter, spanning the putative transcription start site and Exons 1 and 2; the gene promoter was fully methylated in nonYUCHL1-expressed HeLa cells (28) . Our study revealed that the UCHL1 promoter region has very low levels of DNA methylation in control samples. This finding correlates with the abundance of UCHL1 in the brain, constituting up to 2% of total protein (41) . Inclusion of the study of UCHL1 in the present context was because previous studies demonstrated a reduced expression of UCHL1 mRNA and protein levels in the cerebral cortex in DLB (42), thus making CpG methylation at the UCHL1 promoter a putative mechanism of reduced UCHL1 mRNA expression and, therefore, a good candidate gene for comparative purposes. No differences in CpG methylation sites were observed in DLB cases when compared with controls.
Wang et al (39) recently reported 12 potential AD lowmethylated loci in late-onset AD. Similar sites are observed in other neurodegenerative diseases including AGD, PiD, FTLD-tau, FTLD-U, FTLD-MND, PD, DLBp, and DLBc, indicating that putative sites are not exclusive to AD but rather are common in control and disease cases. Importantly, low methylation sites are susceptible to drug intervention. In this regard, putative binding sites to Sp1 and Ets family factors, such as Elk1, occur in the low-methylated j118/+178 region of PSEN1 (43, 44) . Therefore, methylation by specific drugs might reduce the expression of PSEN1 and eventually curve A-amyloid deposition in AD. Indeed, S-adenosylmethionine administration in cell lines downregulates PSEN1 and reduces A-amyloid production and is thus a putative candidate for the treatment of AD (45, 46) . Moreover, deprivation of S-adenosylmethionine upregulates PSEN1 and increases A-amyloid deposits in APP transgenic mice (47) .
It is worth noting that the MAPT loci analyzed in the present study contain binding sites for Sp1, upstream stimulatory factor (USF1), XBP-1, ZNF219, heat-shock transcription factor 2, FAP-2, MAZ, Elk1, AP1, and NFKA, and that all of these putative binding sites are hypomethylated. All of these transcription factors regulate tau expression (48Y52) or have been implicated in brain function (53Y58). ZNF219 is a member of the Kruppel-like zinc finger family that acts as a repressor (59), but its function in the central nervous system is not known.
The present findings in this very large number of cases and regions have shown the following: 1) preservation of CpG methylation of gene promoters with postmortem delay, thus enabling the study of DNA methylation in human postmortem brain; 2) highly reproducible methylation sites for a given gene in control and diseased cases in the human frontal cortex and hippocampus; and 3) a lack of significant modifications in the methylation state of selected loci in disease cases when compared with controls and among various pathological entities.
It is important to stress, however, that all of these studies were carried out in total homogenates of only relatively circumscribed areas that include presumed normal and damaged neurons and different populations of glial and other cells. Therefore, small changes in methylation of DNA promoters might have gone undetected. This caveat is particularly important in neurodegenerative diseases because they are long-lasting disorders in which small methylation changes might be sufficient to modulate their progression.
